Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
EGFR and EGFRvIII analysis is of current interest in glioblastoma- the most common malignant primary CNS tumour, because of new EGFRvIII vaccine trials underway. EGFR activation in glioblastoma promotes cellular proliferation via activation of MAPK and PI3K-Akt pathways and EGFRvIII is the most comm...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00005/full |
| _version_ | 1818907346658656256 |
|---|---|
| author | Emily ePadfield Hayley Patricia Ellis Kathreena M Kurian |
| author_facet | Emily ePadfield Hayley Patricia Ellis Kathreena M Kurian |
| author_sort | Emily ePadfield |
| collection | DOAJ |
| description | EGFR and EGFRvIII analysis is of current interest in glioblastoma- the most common malignant primary CNS tumour, because of new EGFRvIII vaccine trials underway. EGFR activation in glioblastoma promotes cellular proliferation via activation of MAPK and PI3K-Akt pathways and EGFRvIII is the most common variant, leading to constitutively active EGFR. This review explains EGFR and EGFRvIII signalling in GBM; describes targeted therapy approaches to date including tyrosine kinase inhibitor, antibody-based therapies, vaccines and preclinical RNA-based therapies and discusses the difficulties encountered with these approaches including pathway redundancy and intratumoural heterogeneity. |
| first_indexed | 2024-12-19T21:53:40Z |
| format | Article |
| id | doaj.art-d160c2ab2a5245e1a30ae34635b99990 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-19T21:53:40Z |
| publishDate | 2015-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d160c2ab2a5245e1a30ae34635b999902022-12-21T20:04:21ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2015-01-01510.3389/fonc.2015.00005125648Current therapeutic advances targeting EGFR and EGFRvIII in glioblastomaEmily ePadfield0Hayley Patricia Ellis1Kathreena M Kurian2University of BristolUniversity of BristolUniversity of BristolEGFR and EGFRvIII analysis is of current interest in glioblastoma- the most common malignant primary CNS tumour, because of new EGFRvIII vaccine trials underway. EGFR activation in glioblastoma promotes cellular proliferation via activation of MAPK and PI3K-Akt pathways and EGFRvIII is the most common variant, leading to constitutively active EGFR. This review explains EGFR and EGFRvIII signalling in GBM; describes targeted therapy approaches to date including tyrosine kinase inhibitor, antibody-based therapies, vaccines and preclinical RNA-based therapies and discusses the difficulties encountered with these approaches including pathway redundancy and intratumoural heterogeneity.http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00005/fullEGFRmolecular markerglioblastoma multiforme (GBM)EGFRvIIIEFGR inhibitors |
| spellingShingle | Emily ePadfield Hayley Patricia Ellis Kathreena M Kurian Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma Frontiers in Oncology EGFR molecular marker glioblastoma multiforme (GBM) EGFRvIII EFGR inhibitors |
| title | Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma |
| title_full | Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma |
| title_fullStr | Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma |
| title_full_unstemmed | Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma |
| title_short | Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma |
| title_sort | current therapeutic advances targeting egfr and egfrviii in glioblastoma |
| topic | EGFR molecular marker glioblastoma multiforme (GBM) EGFRvIII EFGR inhibitors |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00005/full |
| work_keys_str_mv | AT emilyepadfield currenttherapeuticadvancestargetingegfrandegfrviiiinglioblastoma AT hayleypatriciaellis currenttherapeuticadvancestargetingegfrandegfrviiiinglioblastoma AT kathreenamkurian currenttherapeuticadvancestargetingegfrandegfrviiiinglioblastoma |